Maturation of dendritic cells by bacterial immunomodulators

被引:41
作者
Spisek, R
Brazova, J
Rozkova, D
Zapletalova, K
Sediva, A
Bartunkova, H
机构
[1] Charles Univ, Fac Med 2, Inst Immunol, Prague 15006 5, Czech Republic
[2] Ctr Cell Therapy & Tissue Implants, Fac Med 2, Prague 15006 5, Czech Republic
[3] Fac Hosp Motol, Prague 15006 5, Czech Republic
关键词
dendritic cell; maturation; immunotherapy; bacterial immunomodulators;
D O I
10.1016/j.vaccine.2004.01.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dendritic cells (DC) become fully functional upon maturation by various stimuli. We tested whether an immunostimulatory effect of clinically used immunomodulators (Luivac(R), Biostim(R), Ribomunyl(R), Imudon(R), Bronchovaxom(R)) is caused by direct DC activation. We found that Luivac(R), Biostim(R) and Ribomunyl(R) have a very high DC stimulatory potential in vitro. The level of DC activation was comparable or higher than DC maturation induced by standard maturation stimuli, Poly (I:C) or lipopolysaccharide. Treated DC had activated phenotype, reduced phagocytic activity and they induced the proliferation of allogeneic T lymphocytes. These results are important for understanding the physiology of action of these widely prescribed agents. Administration of bacterial immunomodulators should be considered with care to avoid the potential risk of inducing an autoimmune disease. They could also be used as well-defined maturating agents in the protocols used for the ex vivo production of DC-based vaccines for clinical trials. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2761 / 2768
页数:8
相关论文
共 21 条
  • [1] Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells
    Albert, ML
    Jegathesan, M
    Darnell, RB
    [J]. NATURE IMMUNOLOGY, 2001, 2 (11) : 1010 - 1017
  • [2] Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
    Alexopoulou, L
    Holt, AC
    Medzhitov, R
    Flavell, RA
    [J]. NATURE, 2001, 413 (6857) : 732 - 738
  • [3] Immunobiology of dendritic cells
    Banchereau, J
    Briere, F
    Caux, C
    Davoust, J
    Lebecque, S
    Liu, YT
    Pulendran, B
    Palucka, K
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 767 - +
  • [4] Identification of a clinical-grade maturation factor for dendritic cells
    Boccaccio, C
    Jacod, S
    Kaiser, A
    Boyer, A
    Abastado, JP
    Nardin, A
    [J]. JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01): : 88 - 96
  • [5] Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans
    Dhodapkar, MV
    Steinman, RM
    [J]. BLOOD, 2002, 100 (01) : 174 - 177
  • [6] Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
    Dhodapkar, MV
    Steinman, RM
    Krasovsky, J
    Munz, C
    Bhardwaj, N
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) : 233 - 238
  • [7] Dendritic cells in cancer immunotherapy
    Fong, L
    Engleman, EG
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 245 - 273
  • [8] Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells
    Gilliet, M
    Liu, YJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (06) : 695 - 704
  • [9] Innate immune recognition
    Janeway, CA
    Medzhitov, R
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 : 197 - 216
  • [10] OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway
    Jeannin, P
    Renno, T
    Goetsch, L
    Miconnet, I
    Aubry, JP
    Delneste, Y
    Herbault, N
    Baussant, T
    Magistrelli, G
    Soulas, C
    Romero, P
    Cerottini, JC
    Bonnefoy, JY
    [J]. NATURE IMMUNOLOGY, 2000, 1 (06) : 502 - 509